Selective inhibition of glycogen synthase kinase 3α corrects pathophysiology in a mouse model of fragile X syndrome
Copyright © 2020 The Authors, some rights reserved. Fragile X syndrome is caused by FMR1 gene silencing and loss of the encoded fragile X mental retardation protein (FMRP), which binds to mRNA and regulates translation. Studies in the Fmr1-/y mouse model of fragile X syndrome indicate that aberrant...
Main Authors: | McCamphill, Patrick K. (Author), Stoppel, Laura J. (Author), Senter, Rebecca K. (Author), Lewis, Michael C. (Author), Heynen, Arnold J. (Author), Stoppel, David C. (Author), Sridhar, Vinay (Author), Collins, Katie A. (Author), Shi, Xi (Author), Pan, Jen Q. (Author), Madison, Jon (Author), Cottrell, Jeffrey R. (Author), Huber, Kimberly M. (Author), Scolnick, Edward M. (Author), Holson, Edward B. (Author), Wagner, Florence F. (Author), Bear, Mark F. (Author) |
---|---|
Format: | Article |
Language: | English |
Published: |
American Association for the Advancement of Science (AAAS),
2022-03-14T18:03:06Z.
|
Subjects: | |
Online Access: | Get fulltext |
Similar Items
-
Selective inhibition of glycogen synthase kinase 3α corrects pathophysiology in a mouse model of fragile X syndrome
by: McCamphill, Patrick K, et al.
Published: (2021) -
mGluR5 Negative Modulators for Fragile X: Treatment Resistance and Persistence
by: David C. Stoppel, et al.
Published: (2021-09-01) -
mGluR5 Negative Modulators for Fragile X: Treatment Resistance and Persistence
by: Stoppel, David C, et al.
Published: (2021) -
β-Arrestin2 Couples Metabotropic Glutamate Receptor 5 to Neuronal Protein Synthesis and Is a Potential Target to Treat Fragile X
by: Laura J. Stoppel, et al.
Published: (2017-03-01) -
ß-Arrestin2 Couples Metabotropic Glutamate Receptor 5 to Neuronal Protein Synthesis and Is a Potential Target to Treat Fragile X
by: Auerbach, Benjamin D., et al.
Published: (2017)